The Asia Pacific Clinical Chemistry Analyzers Market should witness market growth of 6.1% CAGR during the forecast period (2023-2030).
Clinical chemistry analyzers conduct assays on samples like blood, urine, cerebrospinal fluid, and plasma to find the presence of analytes linked to illness or medications. The market, which is currently embracing informatics and automation, has seen a significant transformation because of a large part of computer technology. Clinical chemistry automation has increased throughput, allowing for much higher testing volumes, more efficiency, and reduced human error. A high level of biohazard safety is also provided by automated clinical chemistry analyzers, which have demonstrated their effectiveness in reducing cross-contamination. As a result, the utilization of automated chemistry analyzers has significantly increased recently, and the trend is expected to continue over the coming years.
Due to several causes, including the aging population expansion and the rise in chronic and lifestyle diseases, the market is expanding. In accordance with a WHO article, biological aging is caused by the accumulative effects of a range of damage to cells and molecules over time. This causes a steady decline in mental and physical ability, a rise in the risk of illness, and, finally, mortality. These alterations do not follow a linear or regular pattern; they are only tangentially related to an individual's age in years. Therefore, there is a growing need for clinical diagnostics because of the vulnerability of the aging population to various chronic diseases. As a result, the market is anticipated to rise rapidly over the coming years.
According to the International Agency for Research on Cancer (IARC), 63,439 instances of multiple myeloma were discovered in Asia Pacific in 2020. Additionally, the IARC stated there were 230650, 241270, 31742, and 23753 cases of leukemia, non-Hodgkin lymphoma, Hodgkin lymphoma, and cutaneous melanoma in this region, respectively. According to projections made by the National Library of Medicine, 88,249 new cases of leukemia will be diagnosed in China by 2022. Using the same source, 22,450 people were thought to have multiple myeloma.
Government investment and reform efforts have been prioritized, contributing to the nation's tremendous growth. In India, a higher proportion of children have unfavorable cytogenetics, despite the dearth of knowledge about this subject. The need for effective therapy and quick diagnosesis expected to rise because this region has so many kids. For instance, India would have over 444 million children (aged 0 to 18), according to a recent United Nations International Children's Emergency Fund forecast. So, the expansion of the regional market is being aided by all these elements.
The China market dominated the Asia Pacific Clinical Chemistry Analyzers Market by Country in 2022, and would continue to be a dominant market till 2030; thereby, achieving a market value of $1,259.3 million by 2030. The Japan market is registering a CAGR of 5.4% during (2023-2030). Additionally, The India market would showcase a CAGR of 6.7% during (2023-2030).
Based on End-user, the market is segmented into Hospitals & Clinics, Diagnostic Laboratories, Research Laboratories & Institutes, and Others. Based on Test Type, the market is segmented into Basic Metabolic Panel, Renal Profile, Liver Panel, Lipid Profile, Thyroid Function Panel, Electrolyte Panel, and Specialty Chemical Tests. Based on Product, the market is segmented into Reagents, Analyzers, and Others. Based on countries, the market is segmented into China, Japan, India, South Korea, Singapore, Malaysia, and Rest of Asia Pacific.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include F. Hoffmann-La Roche Ltd., Danaher Corporation, Abbott Laboratories, Thermo Fisher Scientific, Inc., Siemens Healthineers AG (Siemens AG), Horiba Ltd., Sysmex Corporation, Hitachi, Ltd., EKF Diagnostics Holdings plc and Ortho-Clinical Diagnostics, Inc. (QuidelOrtho Corporation).
Clinical chemistry analyzers conduct assays on samples like blood, urine, cerebrospinal fluid, and plasma to find the presence of analytes linked to illness or medications. The market, which is currently embracing informatics and automation, has seen a significant transformation because of a large part of computer technology. Clinical chemistry automation has increased throughput, allowing for much higher testing volumes, more efficiency, and reduced human error. A high level of biohazard safety is also provided by automated clinical chemistry analyzers, which have demonstrated their effectiveness in reducing cross-contamination. As a result, the utilization of automated chemistry analyzers has significantly increased recently, and the trend is expected to continue over the coming years.
Due to several causes, including the aging population expansion and the rise in chronic and lifestyle diseases, the market is expanding. In accordance with a WHO article, biological aging is caused by the accumulative effects of a range of damage to cells and molecules over time. This causes a steady decline in mental and physical ability, a rise in the risk of illness, and, finally, mortality. These alterations do not follow a linear or regular pattern; they are only tangentially related to an individual's age in years. Therefore, there is a growing need for clinical diagnostics because of the vulnerability of the aging population to various chronic diseases. As a result, the market is anticipated to rise rapidly over the coming years.
According to the International Agency for Research on Cancer (IARC), 63,439 instances of multiple myeloma were discovered in Asia Pacific in 2020. Additionally, the IARC stated there were 230650, 241270, 31742, and 23753 cases of leukemia, non-Hodgkin lymphoma, Hodgkin lymphoma, and cutaneous melanoma in this region, respectively. According to projections made by the National Library of Medicine, 88,249 new cases of leukemia will be diagnosed in China by 2022. Using the same source, 22,450 people were thought to have multiple myeloma.
Government investment and reform efforts have been prioritized, contributing to the nation's tremendous growth. In India, a higher proportion of children have unfavorable cytogenetics, despite the dearth of knowledge about this subject. The need for effective therapy and quick diagnosesis expected to rise because this region has so many kids. For instance, India would have over 444 million children (aged 0 to 18), according to a recent United Nations International Children's Emergency Fund forecast. So, the expansion of the regional market is being aided by all these elements.
The China market dominated the Asia Pacific Clinical Chemistry Analyzers Market by Country in 2022, and would continue to be a dominant market till 2030; thereby, achieving a market value of $1,259.3 million by 2030. The Japan market is registering a CAGR of 5.4% during (2023-2030). Additionally, The India market would showcase a CAGR of 6.7% during (2023-2030).
Based on End-user, the market is segmented into Hospitals & Clinics, Diagnostic Laboratories, Research Laboratories & Institutes, and Others. Based on Test Type, the market is segmented into Basic Metabolic Panel, Renal Profile, Liver Panel, Lipid Profile, Thyroid Function Panel, Electrolyte Panel, and Specialty Chemical Tests. Based on Product, the market is segmented into Reagents, Analyzers, and Others. Based on countries, the market is segmented into China, Japan, India, South Korea, Singapore, Malaysia, and Rest of Asia Pacific.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include F. Hoffmann-La Roche Ltd., Danaher Corporation, Abbott Laboratories, Thermo Fisher Scientific, Inc., Siemens Healthineers AG (Siemens AG), Horiba Ltd., Sysmex Corporation, Hitachi, Ltd., EKF Diagnostics Holdings plc and Ortho-Clinical Diagnostics, Inc. (QuidelOrtho Corporation).
Scope of the Study
By End-user
- Hospitals & Clinics
- Diagnostic Laboratories
- Research Laboratories & Institutes
- Others
By Test Type
- Basic Metabolic Panel
- Renal Profile
- Liver Panel
- Lipid Profile
- Thyroid Function Panel
- Electrolyte Panel
- Specialty Chemical Tests
By Product
- Reagents
- Analyzers
- Others
By Country
- China
- Japan
- India
- South Korea
- Singapore
- Malaysia
- Rest of Asia Pacific
Key Market Players
List of Companies Profiled in the Report:
- F. Hoffmann-La Roche Ltd.
- Danaher Corporation
- Abbott Laboratories
- Thermo Fisher Scientific, Inc.
- Siemens Healthineers AG (Siemens AG)
- Horiba Ltd.
- Sysmex Corporation
- Hitachi, Ltd.
- EKF Diagnostics Holdings plc
- Ortho-Clinical Diagnostics, Inc. (QuidelOrtho Corporation)
Unique Offerings
- Exhaustive coverage
- The highest number of Market tables and figures
- Subscription-based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free
Table of Contents
Chapter 1. Market Scope & Methodology
Chapter 2. Market at a Glance
Chapter 3. Market Overview
Chapter 4. Asia Pacific Clinical Chemistry Analyzers Market by End User
Chapter 5. Asia Pacific Clinical Chemistry Analyzers Market by Test Type
Chapter 6. Asia Pacific Clinical Chemistry Analyzers Market by Product
Chapter 7. Asia Pacific Clinical Chemistry Analyzers Market by Country
Chapter 8. Company Profiles
Companies Mentioned
- F. Hoffmann-La Roche Ltd.
- Danaher Corporation
- Abbott Laboratories
- Thermo Fisher Scientific, Inc.
- Siemens Healthineers AG (Siemens AG)
- Horiba Ltd.
- Sysmex Corporation
- Hitachi, Ltd.
- EKF Diagnostics Holdings plc
- Ortho-Clinical Diagnostics, Inc. (QuidelOrtho Corporation)
Methodology
LOADING...
